Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors

Abstract

CPH-I is a potential tumor index that is independent of menopausal status. It might be applied as a simple alternative to ROMA in settings of basic medical care.

CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

“…With regard to the diagnostic value of the four indices, we found that the AUC-ROC of HE4, ROMA, and CPH-I were bigger than that of CA125 (0.807, 0.807, and 0.810 vs. 0.694, P < 0.001). However, our AUC of ROMA and CPH-I were much higher than that reported in Minar et al's study (0.65 and 0.67, respectively) when distinguishing 42 BOT I+II patients from 33 EOC I+II patients [15]. The difference maybe mainly due to different races which may cause different proportions of pathological subtypes in ovarian tumors [27–29], further resulting in different ROMA and CPH-I [20, 21].…”

“…Studies showed that levels of HE4 and CA125 and the ROMA index were all higher in EOC I-IV than that of BOT I-IV [16, 20, 24, 25], with other two studies reporting the same trend for CPH-I [15, 19]. Moreover, Kotowicz et al showed that levels of HE4 and CA125 and the ROMA index were all higher in EOC I+II than BOT I-IV [26].…”

“…Therefore, it is particularly necessary to find sensitive and specific indicators to differentiate BOT from EOC before clinical operation, which may be helpful for pathologists. CA125, HE4, and ROMA have been widely used in the differentiation of EOC and benign tumors [13–15], although they were affected by the menopausal status [16]. CPH-I, a new tumor index calculated by HE4, CA125, and age rather than menopausal status with different definitions [15, 17, 18], was thought to be easier to obtain than ROMA clinically [15].…”

“…CA125, HE4, and ROMA have been widely used in the differentiation of EOC and benign tumors [13–15], although they were affected by the menopausal status [16]. CPH-I, a new tumor index calculated by HE4, CA125, and age rather than menopausal status with different definitions [15, 17, 18], was thought to be easier to obtain than ROMA clinically [15]. Researches have shown that CPH-I and ROMA have similar discriminatory performance in benign lesions and malignant ovarian tumors [15, 19].…”

“…CPH-I, a new tumor index calculated by HE4, CA125, and age rather than menopausal status with different definitions [15, 17, 18], was thought to be easier to obtain than ROMA clinically [15]. Researches have shown that CPH-I and ROMA have similar discriminatory performance in benign lesions and malignant ovarian tumors [15, 19]. Studies have also shown that CA125 and HE4 have different manifestations in different pathological types and subtypes of ovarian tumors [20, 21].…”